ELOTUZUMAB INJ,LYPHL
Clinical Criteria Summary
Laboratory & Hematologic Criteria
- Exclusion: Hemoglobin < 8 g/dL; Must transfuse to hemoglobin above 8 gm/dL prior to therapy initiation
- Exclusion: Absolute neutrophil count (ANC) < 1000/mm3
- Exclusion: Platelet count < 50,000/mm3 (<30,000/mm3 if myeloma involvement in bone marrow > 50%)
- Exclusion: Total bilirubin > 2x the upper limit of the normal range (except for Gilbert Syndrome: direct bilirubin > 2 mg/dL) or ALT and AST > 3x upper limit of normal
Clinical Status & Performance
- Exclusion: Eastern Cooperative Oncology Group performance status > 2
Infection, Pregnancy & Lactation
- Exclusion: Active or uncontrolled infection
- Exclusion: Known pregnancy
- Exclusion: Lactating
Diagnosis & Care Setting
- Inclusion: Diagnosis of relapsed or refractory multiple myeloma, following at least one prior line of therapy
- Inclusion: Care is provided by a VA or VA Community Care hematology/oncology provider
Palliative Care
- Inclusion: Goals of care and role of Palliative Care consult have been discussed and documented
Contraception & REMS Compliance
- Inclusion: Patients who can become pregnant and patients with partners who can become pregnant must comply with pregnancy testing and contraception requirements for lenalidomide or pomalidomide under their REMS programs